Therapeutic approaches to Epstein-Barr virus cancers

被引：13

作者：

Soldan, Samantha S. ^{[1
]}

Messick, Troy E. ^{[1
]}

Lieberman, Paul M. ^{[1
]}

机构：

[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

来源：

CURRENT OPINION IN VIROLOGY | 2022年 / 56卷

关键词：

ORIGIN-BINDING PROTEIN; T-CELLS; LYTIC CYCLE; NASOPHARYNGEAL CARCINOMA; ADOPTIVE IMMUNOTHERAPY; VACCINE DEVELOPMENT; CRYSTAL-STRUCTURE; IMMUNE-RESPONSE; SMALL MOLECULES; DNA VACCINE;

D O I：

10.1016/j.coviro.2022.101260

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers. © 2022 Elsevier B.V.

引用

页数：10

共 102 条

[11] Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells [J].

Bu, Wei ;

Joyce, M. Gordon ;

Hanh Nguyen ;

Banh, Dalton V. ;

Aguilar, Fiona ;

Tariq, Zeshan ;

Yap, Moh Lan ;

Tsujimura, Yusuke ;

Gillespie, Rebecca A. ;

Tsybovsky, Yaroslav ;

Andrews, Sarah F. ;

Narpala, Sandeep R. ;

McDermott, Adrian B. ;

Rossmann, Michael G. ;

Yasutomi, Yasuhiro ;

Nabel, Gary J. ;

Kanekiyo, Masaru ;

Cohen, Jeffrey I. .

IMMUNITY, 2019, 50 (05) :1305-+

[12] Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity [J].

Cheng, Adam Z. ;

Yockteng-Melgar, Jaime ;

Jarvis, Matthew C. ;

Malik-Soni, Natasha ;

Borozan, Ivan ;

Carpenter, Michael A. ;

McCann, Jennifer L. ;

Ebrahimi, Diako ;

Shaban, Nadine M. ;

Marcon, Edyta ;

Greenblatt, Jack ;

Brown, William L. ;

Frappier, Lori ;

Harris, Reuben S. .

NATURE MICROBIOLOGY, 2019, 4 (01) :78-+

[13] Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma [J].

Chia, Whay-Kuang ;

Teo, Marissa ;

Wang, Who-Whong ;

Lee, Bernett ;

Ang, Soo-Fan ;

Tai, Wai-Meng ;

Chee, Chit-Lai ;

Ng, Joanna ;

Kan, Rebecca ;

Lim, Wan-Teck ;

Tan, Sze-Huey ;

Ong, Whee-Sze ;

Cheung, Yin-Bun ;

Tan, Eng-Huat ;

Connolly, John E. ;

Gottschalk, Stephen ;

Toh, Han-Chong .

MOLECULAR THERAPY, 2014, 22 (01) :132-139

[14] CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo [J].

Chicaybam, Leonardo ;

Abdo, Luiza ;

Carneiro, Mayra ;

Peixoto, Barbara ;

Viegas, Mariana ;

de Sousa, Priscila ;

Fornazin, Marcia C. ;

Spago, Maria C. ;

Albertoni Laranjeira, Angelo Brunelli ;

de Campos-Lima, Pedro O. ;

Nowill, Alexandre ;

Carvalho Barros, Luciana Rodrigues ;

Bonamino, Martin H. .

HUMAN GENE THERAPY, 2019, 30 (04) :511-522

[15] Vaccine Development for Epstein-Barr Virus [J].

Cohen, Jeffrey I. .

HUMAN HERPESVIRUSES, 2018, 1045 :477-493

[16] Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes [J].

Comoli, P ;

Pedrazzoli, P ;

Maccario, R ;

Basso, S ;

Carminati, O ;

Labirio, M ;

Schiavo, R ;

Secondino, S ;

Frasson, C ;

Perotti, C ;

Moroni, M ;

Locatelli, F ;

Siena, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (35) :8942-8949

[17] Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma [J].

Comoli, P ;

De Palma, R ;

Siena, S ;

Nocera, A ;

Basso, S ;

Del Galdo, F ;

Schiavo, R ;

Carminati, O ;

Tagliamacco, A ;

Abbate, GF ;

Locatelli, F ;

Maccario, R ;

Pedrazzoli, P .

ANNALS OF ONCOLOGY, 2004, 15 (01) :113-117

[18] Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors [J].

Countryman, Jill K. ;

Gradoville, Lyndle ;

Miller, George .

JOURNAL OF VIROLOGY, 2008, 82 (10) :4706-4719

[19] Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350 [J].

Cui, Xinle ;

Cao, Zhouhong ;

Chen, Quanyi ;

Arjunaraja, Swadhinya ;

Snow, Andrew L. ;

Snapper, Clifford M. .

VACCINE, 2016, 34 (34) :4050-4055

[20]

De Clercq Eric, 2003, Expert Rev Anti Infect Ther, V1, P21, DOI 10.1586/14787210.1.1.21

← 1 2 3 4 5 6 7 8 9 10 →